Advertisement
New Zealand markets open in 4 hours 4 minutes
  • NZX 50

    11,836.04
    -39.31 (-0.33%)
     
  • NZD/USD

    0.5901
    -0.0018 (-0.30%)
     
  • ALL ORDS

    7,898.90
    +37.90 (+0.48%)
     
  • OIL

    82.87
    +0.18 (+0.22%)
     
  • GOLD

    2,400.40
    +12.00 (+0.50%)
     

Boston Scientific (NYSE:BSX) shareholders have earned a 14% CAGR over the last five years

It hasn't been the best quarter for Boston Scientific Corporation (NYSE:BSX) shareholders, since the share price has fallen 12% in that time. But at least the stock is up over the last five years. Unfortunately its return of 92% is below the market return of 122%.

So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.

See our latest analysis for Boston Scientific

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

ADVERTISEMENT

During five years of share price growth, Boston Scientific achieved compound earnings per share (EPS) growth of 67% per year. This EPS growth is higher than the 14% average annual increase in the share price. So it seems the market isn't so enthusiastic about the stock these days. Of course, with a P/E ratio of 51.30, the market remains optimistic.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. This free interactive report on Boston Scientific's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

A Different Perspective

Boston Scientific shareholders are up 17% for the year. Unfortunately this falls short of the market return. On the bright side, that's still a gain, and it's actually better than the average return of 14% over half a decade This suggests the company might be improving over time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for Boston Scientific you should be aware of.

Boston Scientific is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.